What type of study is this?

This is a In Vitro Study study (also classified as: Observational).

September 5, 2025Open Access

In-silico study of the bioactive compounds of Blighia sapida koenig revealed a novel Plasmodium falciparum Dihydroorotate dehydrogenase inhibitor for malaria

View Full Paper

Ask AI

Bookmark

Authors

In-silico analysis highlights antimalarial activity of bioactive compounds from B. sapida, suggesting potential for drug development.

Molecular docking studies revealed seven compounds with strong binding affinities to PfDHODH, suggesting effective antimalarial candidates.
Phytol was identified as the most stable inhibitor with RMSD of 0.176, demonstrating promising drug-like characteristics.
GC-MS analysis identified 21 compounds in B. sapida extract, which displayed potential interactions with the target protein PfDHODH.
These findings indicate that bioactive compounds in B. sapida could lead to new treatments for drug-resistant malaria.

Akinyemi et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

September 5, 2025Open Access

View Full Paper

Ask AI

Bookmark

Authors

In-silico analysis highlights antimalarial activity of bioactive compounds from B. sapida, suggesting potential for drug development.

Molecular docking studies revealed seven compounds with strong binding affinities to PfDHODH, suggesting effective antimalarial candidates.
Phytol was identified as the most stable inhibitor with RMSD of 0.176, demonstrating promising drug-like characteristics.
GC-MS analysis identified 21 compounds in B. sapida extract, which displayed potential interactions with the target protein PfDHODH.
These findings indicate that bioactive compounds in B. sapida could lead to new treatments for drug-resistant malaria.

Akinyemi et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark